Goldman Sachs: PTC Therapeutics PTCT Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 105 M | Compra |
1,624,435
+1,006,188
| +163% | +USD 73.3 M | 0.01% | 1074 |
|
|
2026
Q2 | USD 50.4 M | Venta |
618,247
-209,384
| -25% | -USD 15.1 M | ﹤0.01% | 1795 |
|
|
2026
Q1 | USD 56.4 M | Venta |
827,631
-195,460
| -19% | -USD 13.8 M | 0.01% | 1484 |
|
|
2025
Q4 | USD 77.7 M | Compra |
1,023,091
+146,682
| +17% | +USD 10.7 M | 0.01% | 1166 |
|
|
2025
Q3 | USD 53.8 M | Compra |
876,409
+100,656
| +13% | +USD 5.24 M | 0.01% | 1360 |
|
|
2025
Q2 | USD 37.9 M | Compra |
775,753
+173,088
| +29% | +USD 8.22 M | 0.01% | 1545 |
|
|
2025
Q1 | USD 30.7 M | Venta |
602,665
-161,960
| -21% | -USD 8.08 M | 0.01% | 1634 |
|
|
2024
Q4 | USD 34.5 M | Venta |
764,625
-57,816
| -7% | -USD 2.47 M | 0.01% | 1605 |
|
|
2024
Q3 | USD 30.5 M | Compra |
822,441
+31,277
| +4% | +USD 1.05 M | ﹤0.01% | 1674 |
|
|
2024
Q2 | USD 24.2 M | Compra |
791,164
+311,143
| +65% | +USD 10.1 M | ﹤0.01% | 1729 |
|
|
2024
Q1 | USD 14 M | Venta |
480,021
-46,473
| -9% | -USD 1.3 M | ﹤0.01% | 2151 |
|
|
2023
Q4 | USD 14.5 M | Compra |
526,494
+186,608
| +55% | +USD 4.27 M | ﹤0.01% | 2196 |
|
|
2023
Q3 | USD 7.62 M | Venta |
339,886
-86,346
| -20% | -USD 3.21 M | ﹤0.01% | 2623 |
|
|
2023
Q2 | USD 17.3 M | Venta |
426,232
-26,450
| -6% | -USD 1.29 M | ﹤0.01% | 1967 |
|
|
2023
Q1 | USD 21.9 M | Venta |
452,682
-80,352
| -15% | -USD 3.67 M | 0.01% | 1744 |
|
|
2022
Q4 | USD 20.3 M | Compra |
533,034
+27,556
| +5% | +USD 1.15 M | 0.01% | 1942 |
|
|
2022
Q3 | USD 25.4 M | Compra |
505,478
+9,298
| +2% | +USD 456 k | 0.01% | 1660 |
|
|
2022
Q2 | USD 19.9 M | Compra |
496,180
+267,773
| +117% | +USD 9.39 M | 0.01% | 1900 |
|
|
2022
Q1 | USD 8.52 M | Venta |
228,407
-298,926
| -57% | -USD 11.5 M | ﹤0.01% | 2844 |
|
|
2021
Q4 | USD 21 M | Compra |
527,333
+299,114
| +131% | +USD 11.4 M | ﹤0.01% | 2071 |
|
|
2021
Q3 | USD 8.49 M | Venta |
228,219
-41,095
| -15% | -USD 1.69 M | ﹤0.01% | 2878 |
|
|
2021
Q2 | USD 11.4 M | Venta |
269,314
-244,789
| -48% | -USD 10.5 M | ﹤0.01% | 2569 |
|
|
2021
Q1 | USD 24.3 M | Venta |
514,103
-192,787
| -27% | -USD 11.4 M | 0.01% | 1776 |
|
|
2020
Q4 | USD 43.1 M | Compra |
706,890
+321,859
| +84% | +USD 19 M | 0.01% | 1238 |
|
|
2020
Q3 | USD 18 M | Venta |
385,031
-475,814
| -55% | -USD 23.4 M | 0.01% | 1818 |
|
|
2020
Q2 | USD 43.7 M | Compra |
860,845
+259,100
| +43% | +USD 12.7 M | 0.01% | 1056 |
|
|
2020
Q1 | USD 26.8 M | Compra |
601,745
+105,510
| +21% | +USD 5.31 M | 0.01% | 1300 |
|
|
2019
Q4 | USD 23.8 M | Compra |
496,235
+81,650
| +20% | +USD 3.47 M | 0.01% | 1723 |
|
|
2019
Q3 | USD 14 M | Venta |
414,585
-20,507
| -5% | -USD 893 k | ﹤0.01% | 2089 |
|
|
2019
Q2 | USD 19.6 M | Venta |
435,092
-178,935
| -29% | -USD 7.07 M | 0.01% | 1871 |
|
|
2019
Q1 | USD 23.1 M | Compra |
614,027
+83,113
| +16% | +USD 2.79 M | 0.01% | 1745 |
|
|
2018
Q4 | USD 18.2 M | Venta |
530,914
-270,729
| -34% | -USD 9.7 M | 0.01% | 1876 |
|
|
2018
Q3 | USD 37.7 M | Venta |
801,643
-185,860
| -19% | -USD 7.69 M | 0.01% | 1426 |
|
|
2018
Q2 | USD 33.3 M | Compra |
987,503
+566,208
| +134% | +USD 17.7 M | 0.01% | 1523 |
|
|
2018
Q1 | USD 11.4 M | Venta |
421,295
-375,223
| -47% | -USD 9.5 M | ﹤0.01% | 2230 |
|
|
2017
Q4 | USD 13.3 M | Compra |
796,518
+514,068
| +182% | +USD 8.7 M | ﹤0.01% | 2238 |
|
|
2017
Q3 | USD 5.65 M | Compra |
282,450
+54,973
| +24% | +USD 1.08 M | ﹤0.01% | 3033 |
|
|
2017
Q2 | USD 4.17 M | Venta |
227,477
-71,358
| -24% | -USD 961 k | ﹤0.01% | 3214 |
|
|
2017
Q1 | USD 2.94 M | Compra |
298,835
+217,192
| +266% | +USD 2.63 M | ﹤0.01% | 3383 |
|
|
2016
Q4 | USD 891 k | Venta |
81,643
-67,956
| -45% | -USD 713 k | ﹤0.01% | 4556 |
|
|
2016
Q3 | USD 2.1 M | Compra |
149,599
+80,576
| +117% | +USD 655 k | ﹤0.01% | 3795 |
|
|
2016
Q2 | USD 485 k | Compra |
69,023
+56,265
| +441% | +USD 413 k | ﹤0.01% | 4874 |
|
|
2016
Q1 | USD 82 k | Venta |
12,758
-218,285
| -94% | -USD 3.79 M | ﹤0.01% | 6173 |
|
|
2015
Q4 | USD 7.49 M | Compra |
231,043
+160,230
| +226% | +USD 4.72 M | ﹤0.01% | 2486 |
|
|
2015
Q3 | USD 1.89 M | Compra |
70,813
+20,840
| +42% | +USD 891 k | ﹤0.01% | 3856 |
|
|
2015
Q2 | USD 2.4 M | Compra |
49,973
+16,097
| +48% | +USD 939 k | ﹤0.01% | 3659 |
|
|
2015
Q1 | USD 2.06 M | Compra |
33,876
+14,293
| +73% | +USD 872 k | ﹤0.01% | 3752 |
|
|
2014
Q4 | USD 1.01 M | Venta |
19,583
-12,874
| -40% | -USD 567 k | ﹤0.01% | 4547 |
|
|
2014
Q3 | USD 1.43 M | Compra |
+32,457
| Nuevas | +USD 1.02 M | ﹤0.01% | 4250 |
|
|
2014
Q1 | – | Venta |
-17,407
| Cerradas | -USD 295 k | – | 6889 |
|
|
2013
Q4 | USD 295 k | Venta |
17,407
-9,869
| -36% | -USD 173 k | ﹤0.01% | 5707 |
|
|
2013
Q3 | USD 585 k | Compra |
+27,276
| Nuevas | +USD 474 k | ﹤0.01% | 5044 |
|
Otros fondos que tienen PTCT en su portafolio
Posición de Goldman Sachs en PTCT: resumen de T3 2026
Goldman Sachs aumentó su participación en PTC Therapeutics (PTCT) en 163% durante T3 2026, al comprar aproximadamente USD 73.3 M y elevar la posición a 1,624,435 acciones con un valor de USD 105 M. La posición representa 0.01% del portafolio y ocupa el puesto #1074.
Goldman Sachs reportó por primera vez una posición en PTCT en T3 2013 y desde entonces la ha mantenido en 51 trimestres. Al cierre de T3 2026, 361 fondos que sigue Wall St. Rank mantienen una posición en PTCT.
- Al cierre de T3 2026, Goldman Sachs tenía 1,624,435 acciones de PTC Therapeutics con un valor de USD 105 M.
- Goldman Sachs compró 1,006,188 acciones de PTC Therapeutics en T3 2026, por un monto estimado de USD 73.3 M.
- PTC Therapeutics representó el 0.01% del portafolio de Goldman Sachs en T3 2026 y fue su posición número 1074.
- Goldman Sachs reportó por primera vez una posición en PTC Therapeutics en T3 2013 y desde entonces la ha mantenido en 51 trimestres.
- Al cierre de T3 2026, 361 fondos que sigue Wall St. Rank tenían PTC Therapeutics en su portafolio.
Según el informe 13F de Goldman Sachs correspondiente a T3 2026, presentado el 16 nov 2026.